"The global gold standard": Aussie startup Presagen launches its AI fertility app in the UK and Europe – SmartCompany.com.au

Co-founders Dr Jonathan Hall, Dr Michelle Perugini and Dr Don Perugini. Source: Matt Loxton.

An Australian company that uses artificial intelligence to increase the chance of pregnancy through IVF has launched its software application in the UK and Europe.

Life Whisperer, the fertility arm of AI healthcare company Presagen, commercialised its flagship product in Australia in late January and released it through a distributor into India, Sri Lanka and Bangladesh last month.

Approvals are also being sought to sell the South Australian-developed software tool in Japan, Southeast Asia and the US, where it has conducted a number of clinical trials.

Last weeks launch into the UK and Europe is a major step in the three-and-a-half-year journey for the product, which was forced into a COVID-19 hiatus from March to May when many of the worlds fertility clinics closed their doors.

Adelaide-based Presagen currently has 15 staff and small offices in San Francisco and London to drive the global expansion.

Get COVID-19 news you can use delivered to your inbox.

Youll also receive special offers from our partners. You can opt-out at any time.

Presagen co-founder and chief executive Dr Michelle Perugini said the company had strong connections in the UK and Europe and a number of clinics were already trialling the product in the region.

She said getting clinics on board as commercial customers was the next stage.

Regulatory approval in the UK and Europe represents a significant opportunity for Life Whisperer to expand its global presence, and we are very much looking forward to working with clinics and patients across the region, supported from our London offices, she said.

Its a secure web-based application that is completely scalable so we can set up new clinics within minutes anywhere in the world.

The Embryo Viability Application for IVF clinics uses artificial intelligence to analyse images of embryos to assist clinicians to identify which embryo will likely lead to a pregnancy.

By selecting the best embryo, Life Whisperer aims to shorten the time to pregnancy and improve outcomes for couples undergoing IVF treatment.

An international study recently published in the journal Human Reproduction involved blind evaluation of 1600 IVF embryos.

Life Whisperer was shown to perform 25% better than traditional manual methods of embryo assessment by highly experienced embryologists.

The technology was showcased on Tuesday night last week (Australian time) at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology, which is being held online this year.

Internationally renowned fertility expert Matthew (Tex) VerMilyea from Ovation Fertility (US) will present Life Whisperers latest advances in AI for IVF at the event where Presagen will also have a virtual exhibition booth.

Dr Perugini said Presagen was planning a significant capital raise this year to drive growth.

She said the company was looking forward to working with IVF clinics across the globe to offer Life Whisperer to patients at a low cost, meaning more couples could gain more certainty in embryo selection and achieve success sooner, with fewer IVF cycles.

Life Whisperer is poised to become the global gold standard embryo pre-screening tool in IVF, supporting the clinical decision about which embryo is most viable.

This article was first published by The Lead.

NOW READ: Billions in lost revenue, 10,000 jobs lost: How COVID-19 will undermine Australias research capacity

NOW READ: The healthcare industry is buckling under pressure and ripe for disruption, says AirTree investor Jackie Vullinghs

Small and medium businesses and startups have never needed credible, independent journalism and information more than now.

Thats our job at SmartCompany: to keep you informed with the news, interviews and analysis you need to manage your way through this unprecedented crisis.

Now, theres a way you can help us keep doing this: by becoming a SmartCompany supporter.

Even a small contribution will help us to keep doing the journalism that keeps Australias entrepreneurs informed.

Go here to see the original:
"The global gold standard": Aussie startup Presagen launches its AI fertility app in the UK and Europe - SmartCompany.com.au

I found sperm donor on Facebook as I was desperate for a baby, we first met when he came round to give me the – The Sun

A FIRST-TIME mum was so desperate to have a child with her female partner that she used aspermdonor - that she found on FACEBOOK.

Shannon, 20, turned to the social networking site in the hope of finding an affordable way to fall pregnant with her partner, Katie, 25.

6

The pair began to research their options, but didn't like the idea of picking an anonymous donor from a list and couldn't afford the 3k fertility clinic price tag.

Instead, they joined a Facebook group with other hopeful parents and willing donors.

They went on to select a donor from Facebook in April 2019, after being together for seven months, and within two months Shannon fell pregnant via artificial insemination (AI) - using a syringe bought from Amazon to conceive.

Artificial insemination is the process in which a donor'sspermis inserted into the female's body not via sex - but commonly with pipettes and even turkey basters.

6

She gave birth to Ocean Mabel Rose onFebruary 13 this year, weighing a healthy 6lbs 2oz - their first baby together.

Ocean completes their new family of four - as Katie has another child also via a donor, two-year-old Jaycee-Rayne.

Stay-at-home mum Shannon said: "I'm adopted myself, and have never been surrounded by an actual biological family.

"Once Katie and I decided we wanted a baby together, I simply searched online 'Spermdonors UK'.

"I wasnt expecting much, perhaps to see a load of IVF clinics with all these huge prices that I knew I would never be able to afford.

I got lots of strange friend requests from men saying they would be my donor, but 8/10 looked like fake accounts.

"Instead, it linked me to a Facebook group where donors and recipients could find each other and get to know one another - establishing a proper relationship, not all anonymous like the clinics do things.

"I was shocked at first as I thought it was odd. But the more I looked into it, the more I warmed up to the idea.

"Everyone was friendly and we had so many donors messaging us and offering their services. If I was to have another child, this is the only way I'd do it."

New mum Shannon had always dreamed of having her own baby, but knew the costs atspermdonor clinics were out of her budget.

She said: "Ever since I was a kid I wanted to be a mum.

6

"Having a female partner automatically made that process more difficult, but it was just another hurdle to overcome.

"I'd considered aspermdonor in December 2018 when I was single, but then Katie came into my life and things changed."

Meeting on dating app Plenty of Fish, Shannon and full-time-mum Katie instantly clicked and discussed having their own children. Katie was already a mother to then 10-month-old Jaycee-Rayne.

Shannon said: "I expressed to Katie that I wanted to have a child but she wasnt ready at that time, considering how young her daughter was.

"By January 2019 I brought the subject back up and it nearly broke our relationship as she still wasn't ready.

6

"Having a baby was my number one dream, but she had already had her daughter and just wasnt ready to take on another."

Two months later, the couple had another chat, and after some tears and a deep discussion, they decided that they were ready to have a baby of their own.

Unsure where to commence their search for aspermdonor, the pair searched online on a whim for options, and Facebook was the first result that popped up.

The link was to a private Facebook group of hopeful parents andspermdonors offering their services.

Shannon said: "There were hundreds of groups, but I wanted to make sure I wasnt rushing into joining any old one.

The donor really understood the process, and was patient with us without being overbearing or creepy.

"I worried about the motives of some of these donors, but once we saw their STD checks and genetic test results, my mind was put at ease.

"Looks weren't too important to us either, as the DNA pool would be 50/50 anyway. We were more concerned about having a healthy, happy baby over anything cosmetic.

"At first I got lots of strange friend requests from men saying they would be my donor, but 8/10 looked like fake accounts.

"But then I saw more and more posts from women who had been successful with their donors, and it gave me the hope that the right donor would eventually come to me."

In April 2019 Shannon and Katie received the message they had been waiting for - a donor who had previously fathered children through the page.

He provided them with up-to-date health check certificates, photos of himself, his job description and photos of his previous donor children -of which there were 11.

6

Excited Katie said: "I practically jumped with excitement and thought to myself that he was perfect, and the one for us.

"Once we started talking, Shannon let him know the dates on which she would be ovulating, so he could come to our flat in that time-frame and provide hissperm.

"We bought a kit on Amazon which came with an ovulation test, a sterile cup for the donor to leave his sample in, and a syringe so I could insert Shannon with thespermonce the donor had completed his sample."

The donor then came to the pair's flat two times in May and June, taking his sample cup into the bathroom to fill withspermand return it to the couple.

Then, Katie would suck up thespermwith a syringe and insert it into Shannon, who lay down for at least half an hour to ensure thespermwas in her body.

Shannon said: "It was all a bit of a rush, as to maximise the chance of falling pregnant thespermshouldn't be outside of the body for too long. After about 20 minutes thespermcan die, so we couldn't afford to wait if we wanted it to be successful.

"The donor really understood the process, and was patient with us without being overbearing or creepy.

"He said he did it to help women or couples have children he just seemed like a nice man, and always did the job!"

The couple paid the donor's transport costs, and although DIY insemination is not officially unlawful, it is illegal to distributespermintended for human application without a licence issued by theHuman Fertilisation and Embryology Authority.

Donors on Facebook dont have the same rights as theofficial route theyre liable to pay child support if a contract isnt signed and could still see the child if thats what both parties want.

After two attempts, Shannon successfully became pregnant in June 2019."I had such severe morning sickness until week 25 of the pregnancy, but I was elated more than anything to have a safe and healthy baby," she said.

"Our little girl was born naturally at 38 weeks and it was the best day of my life."

6

Shannon was in labour for 16 hours, and with Katie by her side she gave birth on 13th February 2020 to Ocean Mabel Rose.

Shannon said: As soon as I held my baby I knew Id made the right decision. Katie and I were both in tears, and I felt nothing but pure joy. She looked perfect."

There is no fathers name on Ocean's birth certificate and a man who providesspermas a donor gives up his legal rights over the biological child.

The donor will only meet the baby at the request of Shannon and Katie, but he has no legal grounds upon which to request visitation or custody.

Shannon said: "I feel like a new woman.

"We're all doing really well, and Ocean is the most content baby ever.

"The process was so easy and we were so lucky to fall pregnant so quickly.

"We now have the perfect family of four. Facebook gave me a baby, something I never thought I'd say."

How does sperm donation in the UK work?

Sperm donation can help couples struggling to have kids of their own or single women who want to start a family.

If you donate your sperm through a fertility clinic or a sperm bank, you wont have any responsibilities or rights towards a child conceived using your semen.

However, as of April 2005, children conceived through sperm donation do have the right to ask for certain information about their donor once they reach the age of 16.

When they turn 18 they can also request to know the name and last known address of their donor.

The main reason men choose to donate their sperm is to help couples who cant conceive naturally, or if they have a strong desire to pass on their genes to another generation.

In the UK, donation in exchange for payment is prohibited by law.

SUPERMARKET SWEEPMum shares meal planner which has saved her family 360 a month on food

Exclusive

HINCH ITMy entire home is grey just like Mrs Hinch's - we even have the same dog

REPLI-KATELidl is selling a 9.99 dress which is identical to Kate Middletons 449 frock

HOME RUNMum beats empty nest syndrome by making daughter's room a MASSIVE walk-in wardrobe

SPEND A PENNYMums show off their TX Maxx and Wilko bargains including 1p school supplies

CRUSHED ITWoman wanted 360 crushed diamond table so made one using The Range coasters

Meanwhile, super sperm donorMitch KennedybaffledThis Morning viewerswith his plan to prevent incestuous relationships among his expanding brood.

And 66 kids and counting... 'white van man sperm donor' Clive tells more about his remarkable storyhere.

Plus meet Charlotte who had a kid with Clive - one of the UK's most prolific sperm donors.

Read the original post:
I found sperm donor on Facebook as I was desperate for a baby, we first met when he came round to give me the - The Sun

Simple hair test ‘could tell women how many eggs they have left’ – Brinkwire

A simple test of a womans hair could tell women how many eggs they have left by judging levels of a key fertility hormone, scientists say.

US and Spanish researchers found biologically relevant levels of anti-Mllerian hormone (AMH) an indicator of ovarian reserves in womens hair samples.

AMH is a hormone produced by the cells within a womans ovaries and gives an indication of her egg reserves and subsequent fertility.

The hormone is incorporated into the matrix of hair before it reaches the surface of the skin.

Levels of AMH from the hair correlated with levels from blood samples, which is currently the most common method of measuring the hormone.

But taking AHM readings from the hair would be less invasive than a blood sample and a more appropriate representation of hormone levels, according to scientists.

Testing can be done without visiting a clinic, such as by sending a hair sample through the post, which makes this type of test cheaper and available to a broader range of women.

The role of AMH as a measure of ovarian reserve in predicting response to ovarian stimulation for IVF now seems beyond question, researchers add.

Hair is a medium that can accumulate biomarkers over several weeks, while serum is an acute matrix representing only current levels, said Sarthak Sawarkar at US health tech firm MedAnswers, who presented his research online at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology.

While hormone levels in blood can fluctuate rapidly in response to stimuli, hormone levels measured in hair would represent an accumulation over several weeks.

A measurement using a hair sample is more likely to reflect the average hormone levels in an individual.

AMH has become a key marker in the assessment of how women may respond to fertility treatment.

The hormone is produced by small cells surrounding each egg as it develops in the ovary.

Studies have not correlated AMH levels to a reliable chance of live birth, nor to forecasting the time of menopause.

However, AMH measurement has become an intrinsic marker in assessing how a patient will respond to ovarian stimulation for IVF as a normal responder, poor responder (with few eggs), or over-responder (with many eggs and a risk of ovarian hyperstimulation syndrome).

Currently, AMH is presently measured in serum taken from a blood sample drawn intravenously, but readings taken this way represent just a snapshot of a moment in time and are relatively invasive to complete.

To learn more about the potential of AMH readings taken from the hair, researchers collected hair and blood samples 152 women from whom hair were during hospital visits.

AMH was also measured in blood samples from the same subjects, as well as an ultrasound count of developing follicles in the ovary a method known as antral follicle count (AFC).

Biologically relevant AMH levels were successfully detected in the hair samples, which declined with patient age, as expected by the team.

AMH levels from hair strongly correlated with levels as determined by both serum in the blood and AFC.

The hair test was also able to detect a wide range of AMH levels within individuals from a similar age cohort, suggesting a greater accuracy than from a single blood sample.

Hormones accumulate in hair shafts over a period of months, while hormone levels in serum can change over the course of hours, they found, meaning the hair test may be a more reliable measurement.

Hormone levels are also assessed non-invasively, which reduces testing stress and offers a less expensive assay.

This study is very interesting as it suggests AMH can be reliably measured from hair samples as opposed to the standard approach of a blood test, Tim Child, medical director at Oxford Fertility, told the Times.

The AMH level in hair is more likely to be averaged-out over a time period rather than the more instant level in a blood sample.

The question is whether the hair AMH levels correlate to the ovarian response and therefore numbers of eggs collected during an IVF cycle this is not examined in this study.

If the correlation is poor then hair samples will be of no benefit.

If the correlation is as good as, or perhaps even better than with blood AMH, then this technique promises to further simplify the fertility treatment process for women and will be an exciting development.

The results have been presented by PhD student Sarthak Sawarkar, working in the laboratory of Professor Manel Lopez-Bejar in Barcelona, with collaborators from MedAnswers.

See more here:
Simple hair test 'could tell women how many eggs they have left' - Brinkwire

Comparative Anatomy and Histology | ScienceDirect

Comparative Anatomy and Histology: A Mouse and Human Atlas is aimed atthe new mouse investigator as well asmedical and veterinarypathologists who need to expand their knowledge base into comparative anatomy and histology. It guides the reader through normal mouse anatomy and histology using direct comparison to the human. The side by side comparison of mouse and human tissues highlight the unique biology of the mouse, which has great impact on thevalidation of mouse modelsof human disease.

Link:
Comparative Anatomy and Histology | ScienceDirect

When the Facts Change, We Change Our Minds (Anatomy of a Sale) – Yahoo Finance

Even before the coronavirus, we were not big fans of the airlines business. Planes are expensive. Airlines have to pay for them whether they are fully occupied during normal economic times or when they are half-loaded during recessions. Their other big cost is fuel - airlines have little control over it. If they hedge the oil price and it goes up, they are heroes. If they hedge oil and it declines, their unhedged competition will have an economic advantage. It is very difficult to develop competitive advantage; customers usually have very little loyalty and price is the deciding factor for most buying decisions.

Warren Buffett (Trades, Portfolio) invested in the airlines industry in the '80s, lost money, and swore he'd never invest in it again. However, after the Great Financial Crisis the industry went through significant consolidation by mergers and attrition, leaving four carriers controlling the bulk of the market. Fewer competitors made competition more rational and turned these airlines into much better businesses. So Buffett changed his mind and bought a 10% stake in all four of the largest U.S. airlines. For a few years it seemed that he was finally right about the airlines.

Airlines were never our cup of tea. The high fixed-cost structure of the industry and its past history of going bankrupt every other recession made our EQ when it comes to airlines very low. When Buffett bought them, for some value investors, the airlines had been blessed by the high priest. We are agnostic (growing up in Soviet Russia has its rare benefits) and have to own our decisions, so we passed on the airlines without spending much time thinking about them.

Typically, when you go into recession you can look at the rear-view mirror earnings for a cyclical company and that becomes your goalpost for future earnings power within a year or two, max. We don't know how long it will take until we'll again see the 2019 earnings power of airlines and the travel industry in general. Here is what we know. Though it is hard to imagine this today, the fear of COVID-19 will eventually go away, either because there is a vaccine or a cure, or because the virus is gone, or because we will simply adapt to its existence.

But even in absence of a vaccine or cure, we'll change our behavior, and that will happen slowly on the margin. After being locked up for a few months, not seeing friends and relatives except on Zoom or Facetime, we'll timidly visit their houses and sit six feet apart on their porches. (My family did this on Mother's Day.) Then we'll invite very close friends - the ones who stuck religiously to social distancing- to our homes for dinner. Then we might chance visiting a restaurant with outdoor seating. Then, on a rainy day, we'll go inside the restaurant and find that it now has huge spacing between the tables. We'll make a lot of small incremental decisions; each will be a tiny compromise that will nudge us out of our fear.

Of course, each time we read about serious virus flareups, we'll take one step back.

Flying is at one extreme in the spectrum of social distancing. It requires finding your way through airports packed with people and then getting on a plane that, even after the middle seats are removed will still have a higher density than a packed bar on Friday night in Manhattan. Thus flying will require a great many little, incremental, marginal decisions before we overcome the fear of boarding a plane.

Vaccine availability would instantly vanquish fear, and our behavior would come back to normal. Well, almost. There will be scar tissue on the economy - trillions in government debt and persistently high unemployment - that will take time to clear up. People are not flying today because we are in lockdown; they'll be flying less than they used to after lockdown is over because they are still afraid; and after their fear is gone they'll still be flying less because they cannot afford the flights.

We imagine that when Buffett bought airlines in 2015, he thought the worst case would be a significant recession where plane occupancy would fall from the usual 80-90% to 50-60% (according to the FT, only four airlines out of a few hundred are profitable at 62% occupancy). His thinking was that the airlines would lose some money for a few quarters, but the recession would be anything but an existential crisis for them. Recessions last months and expansion years, and he thought he had bought them cheap on full-cycle (both recession and expansion) earnings.

Story continues

Despite being the Oracle of Omaha, he did not foresee that one day we might have a different type of recession where 95% of the planes would be grounded, not because people couldn't afford to buy a tickets but because they would be required to stay home by their governments, or would be afraid that close proximity to others would make them sick or even kill them.

Very few businesses can survive when 95% of their revenue goes away for an extended period of time. Even fewer can survive when they have a large fixed-asset base that needs to be paid for whether they are using it or not.

The sad reality is that unless airlines raise new capital, they will go bankrupt. This capital, though it might save them, will reduce the value of their businesses. Equity issuances, especially at today's depressed stock prices, would permanently dilute shareholders, as future earnings will be shared with a much-increased shareholder base.

If the airlines issue debt, it will not be cheap capital, either, and will burden these companies, which already have a lot of fixed costs, with another cost - significant interest payments that will substantially reduce their future earnings power. The longer the fear of the virus lingers on, the more money these companies will lose and the greater the damage that will be done to their balance sheets and thus their future earnings power.

In our thinking about the virus we have three timelines, or eras: BC - before coronavirus, DC - during coronavirus (now), and AC - after coronavirus (the virus is completely gone, or there is a vaccine or effective treatment. The longer the DC era lasts the more impact it has on the AC era. The DC era comes with high unemployment and enormous government spending - larger deficits and an ever-growing debt pile that is no longer counted in billions but in trillions.

The future of the airlines is path-dependent, and they have little control over that path; it is controlled by the virus (or the fear of the virus).

We don't own airlines, so why am I spending so much time talking about them? There are several reasons. First, because they are companies that are antithetical to our portfolio philosophy. Charlie Munger (Trades, Portfolio) says, "Tell me where I am going to die so I won't go there." So it's worth having a clear picture of the types of businesses you don't want to own.

Second, we wanted to point out Buffett's ability to change his mind. Interestingly, Buffett, who was already the largest shareholder of U.S. airlines, bought more airline stocks a few weeks before he sold them. We did something similar this quarter, too: We increased our position in Melrose Industries, just to sell the full position two weeks later. (More about Melrose to follow).

Third, like Buffett, we were playing traditional chess, not realizing that the game had changed to Fischer random chess. We were following the normal recession handbook (mental models) but then realized that this is anything but a normal recession. We have to be incredibly careful about using our past mental models today; they were built in a very different environment. Today, past experience is not useless, but if relied on blindly it can be dangerous. Some things will play out in the future as they have in the past, but many won't.

We needed to start using a first-principles approach - a concept we shamelessly borrowed from physics. We took out a blank piece of paper, assumed we knew nothing, and instead of continuing to think by analogy, started questioning every assumption we make in our analysis.

Our decision to sell Melrose Industries (LSE:MRO) is very similar to Buffett's sale of the airlines. We sold Melrose before the Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) annual meeting. It was a difficult decision, not because we cemented a loss but because we parted with a business we really liked, that was run by good management, and that was significantly undervalued when we bought it.

When we were buying Melrose we stress-tested it for a severe recession; however, the decline that Melrose is probably experiencing today did not occur to us in our wildest imagination. Melrose is a very strong player in two industries that have been impacted tremendously: the airlines space (it makes parts that go into planes and engines) and car parts (it is one of the largest makers of transmissions for cars). We talked to the company. It has credit lines and cash to give it immediate liquidity, but we are not sure if it will be enough.

We had applied the traditional recession mental model to our analysis, and we were wrong. Given the world we are looking at now, we should have sold it sooner.

Buying new planes is the last thing on airlines' minds today. Also, only 20% of Melrose's business comes from replacement parts. Melrose's auto parts business (ironically, the business we worried about the most when we bought the stock) may be okay; it may even generate some profit; but we are not sure it will be able to sustain the company. We simply don't know what the losses are going to be in the airlines space and for how long. We have a tremendous respect for the Melrose management team - they're a big reason why we bought the stock - but at this point the problem that Melrose is facing is bigger than them.

If you look carefully through your portfolio, you'll see that we've positioned it to the opposite side of spectrum from the airlines. Most of our holdings are concentrated in four industries: defense, healthcare, tobacco (where we are permitted by clients), and telecommunications. These industries have one thing in common: They will not be structurally impacted by the virus.

Consumption of goods and services in the four industries is completely insensitive to the virus. These companies all have very stable cash flows and pricing power - in the event of deflation they'll maintain their prices, while during inflation they'll raise them.

And one more thing...

I am not a journalist or reporter; I am an investor who thinks through writing. This and other investment articles are just my thinking at the point they were written. However, investment research is not static, it is fluid. New information comes our way and we continue to do research, which may lead us to tweak and modify assumptions and thus to change our minds.

We are long-term investors and often hold stocks for years, but as luck may or may not have it, by the time you read this article we may have already sold the stock. I may or may not write about this company ever again. Think of this and other articles as learning and thinking frameworks. But they are not investment recommendations. The bottom line is this. If this article piques your interest in the company I've mentioned, great. This should be the beginning, not the end, of your research.

Vitaliy Katsenelson, CFA

Student of Life

I am the CEO at IMA, which is anything but your average investment firm. (Why? Get our company brochure in your inbox here, or simply visit our website.)

In a brief moment of senility, Forbes magazine called me "the new Benjamin Graham."

I've written two books on investing, which were published by John Wiley & Sons and have been translated into eight languages. (I'm working on a third - you can read a chapter from it, titled "The 6 Commandments of Value Investing" here.)

And if you prefer listening, audio versions of my articles are published weekly at investor.fm.

This article first appeared on GuruFocus.

Read more:
When the Facts Change, We Change Our Minds (Anatomy of a Sale) - Yahoo Finance

Greys Anatomy Season 17: Greys Anatomy : Official Journal On The Start ? – Auto Freak

Season 17 of Greys Anatomy is in complete preparation. Everybody wonders what will happen to Oj following the passing of Alex.

In a month or two, fans of Greys Anatomy will have the ability to observe the year 17. But we are asked whatll happen to Oj following the departure of Alex. Beware; the report contains spoilers.

- Advertisement -

Fans of Greys Anatomy havent been able to see all of the episodes of season 16. In reality, because of the Covid-19, the series runners havent released the previous four episodes of this year.

That the fans have frustrated since the last episode gave a play. Nonetheless, the season has not been without turns and twists, and fans have had to confront the departure of a personality flagship.

In fact, Alex played with Justin Chambers has selected to depart Seattle in order to help his unwell mom. The latter wanted to become present for his family, and hes left behind him, his wife.

It will not seem like Alex when we know that he loves Jo, and they had just gotten married. As well, the fans are disappointed, and everybody is wondering what will happen to Jo from the year 17 of Greys Anatomy.

Jo has created a big depression, and she recovered just out of his trauma from the sequence. Therefore, the departure of Alex could well mark the conclusion of the narrative of the physician. This last one may choose to leave for Greys Anatomy.

Chris Carmack that plays Lincoln, ensures that the character of Jo is strong. Thus, according to him, the woman Karev should recuperate. I do not believe that you can get rid of it easily; shes really tough skin. And she has a great deal to give to the planet and to his patients at Grey Sloan, he explained.

Hence, Oj should be present in Greys Anatomys season 17. Shell be able to rely upon the existence of his family to create a cross on his history with Alex. Additionally, it will be a little nearer to Lincoln.

In fact, Jo is very familiar with Lincoln, and they wish to be accomplices. One may even believe that they may end up going out together from the new season. But until now, Lincoln is in a relationship with Amelia, and they come just to get a child

- Advertisement -

Read the original:
Greys Anatomy Season 17: Greys Anatomy : Official Journal On The Start ? - Auto Freak

ACMG’s Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019–Journal is Ranked 13th of 177 Journals in Genetics & Heredity -…

BETHESDA, Md., July 8, 2020 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) announced today that the 2019 Journal Impact Factors, published by Clarivate Analytics in the latest edition of Journal Citation Reports, calculated an impact factor of 8.904 for ACMG's official journal, Genetics in Medicine (GIM). This is the second highest Impact Factor in the journal's history and ranks GIM 13th of 177 titles in the Genetics & Heredity category.

The Impact Factor is an objective measure of the world's leading journals, based on articles' cited references and is oft considered a measure of a journal's impact, overall successful performance and relevance to its field. The most highly cited article in GIM in 2019 was "Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics."

"GIM's editors and editorial staff are delighted that our Impact Factor has increased from last year. This improvement in the Impact Factor once again demonstrates that the journal remains one of the most widely read and cited journals publishing clinically relevant research in the life sciences," said GIM's Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG."We are most thankful to the peer reviewers who put in countless hours to help maintain the outstanding quality of articles and the authors who trust us to disseminate their groundbreaking scholarly work. The Impact Factor is one of a number of metrics used to evaluate journals, and a journal should not be evaluated solely on that one metric. Genetics in Medicine'scontinued success and relevance is also reflected in our very high overall downloads and reads as well as a prominent social media presence."

ACMG CEO Maximilian Muenke, MD, FACMG said, "As the CEO of the ACMG, I am extremely proud of 'our' journal. As a physician-scientist who before joining ACMG worked in academic settings where publishing in high-impact factor journals was the goal, I am well aware of the importance of this metric. My congratulations and gratitude on increasing GIM's impact factor go to Bob Steiner, Jan Higgins, the GIM staff and the entire editorial team to make this success happen!"

Genetics in Medicineis published by Springer Nature. The journal, published since 1998, is supported by an expert board of editors representing all facets of genetic and genomic medicine, including biochemical and molecular genetics, cytogenetics, and the application of genetics and genomics to other medical specialties such as oncology, cardiology, neurology, pediatrics, ophthalmology and maternal-fetal medicine.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Continued here:
ACMG's Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019--Journal is Ranked 13th of 177 Journals in Genetics & Heredity -...

Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),…

New York, July 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05930381/?utm_source=GNW

Product Type:Kits, Consumables, and Services Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Russia, Netherlands Asia-Pacific Japan, China, India, Australia, Singapore Latin America Brazil, Mexico Rest-of-the-World Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation North America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Europe Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Latin America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Rest-of-the-World Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers Rising Prevalence of Genetic Disorders Increasing Prevalence of Various Types of Cancer, Globally Increasing Research Funding in the Field of Genomics

Market Challenges Expensive Sequencing Procedures and Their Applications in Medical Treatments High Capital Requirement Hampering the Expansion of Global Reach Stringent Regulatory Standards

Market Opportunities Technological Advancements for Exome Sequencing Rise of Direct-to-Consumer (DTC) Testing Services Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies ProfiledAgilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report: What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum? What are the major market drivers, challenges, and opportunities in the hereditary genetic testing? What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market? How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends? How each segment of the market is expected to grow during the forecast period from 2020 to 2030? Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future, and why? What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area? What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market? What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market OverviewThe hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends.The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace.

However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth.The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry.

Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany France Italy U.K. Spain Russia Netherlands Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-World (RoW)Read the full report: https://www.reportlinker.com/p05930381/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original here:
Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),...

Researchers Discover Genetic Variants Linked to Type 2 Diabetes – HealthITAnalytics.com

July 08, 2020 -In the largest study of its kind, researchers discovered hundreds of novel genetic variants linked to type 2 diabetes, potentially improving care for millions living with this disease.

A team from the Perelman School of Medicine at the University of Pennsylvania and the Veterans Health Administrations (VHA) Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC) examined the genes of more than 200,000 people around the world with type 2 diabetes.

In addition to uncovering new genetic variants linked to the condition, researchers identified gene variants that vary by ethnicity, as well as variants tied to conditions related to type 2 diabetes like coronary heart disease and chronic kidney disease.

The group used data from the worlds largest biobank, the Million Veteran Program (MVP) in the VHA, as well as data from the DIAGRAM Consortium, the UK Biobank, the Penn Medicine Biobank, and Biobank Japan. Researchers analyzed a study population of 1.4 million people around the world, of whom almost 230,000 had type 2 diabetes.

The team then broke down the genetic makeup of those hundreds of thousands with type 2 diabetes and found 558 independent genetic variants that are differentially distributed between people with and without type 2 diabetes. Twenty-one of these variants were specific to European ancestry while seven were specific to African American ancestry. Of the 558 variants found, 286 had never been discovered.

Researchers set out to discover if certain genetic variants among this group of people could be linked to specific type 2 diabetes-related conditions.

Ultimately, three were linked to coronary heart disease, two to acute ischemic stroke, four to retinopathy, two to chronic kidney disease, and one to neuropathy, saidMarijana Vujkovic, PhD, a biostatistician at both the Perelman School of Medicine at the University of Pennsylvania, VHAs CMCVAMC and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

Building on this research, the scientific community can assess which of the surrounding genes nearby the identified genetic variants is likely to be the causal gene that alters the risk of type-2 diabetes, and that could lead to early interventions to limit controllable risks of developing the condition.

While the researchers found many genetic variants in people with type 2 diabetes, no one variant was labeled as the worst or most dangerous.

However, just like heart disease, schizophrenia, or obesity, it is the accumulation of a large number of these variants that can add up to a considerable increase in risk, said co-senior authorBenjamin F. Voight, PhD, an associate professor of Systems Pharmacology and Translational Therapeutics at Penn, and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

We hope this study can not only help find that subset of patients with substantial risk, but also to motivate new, future studies for treatments based on these findings.

Knowing more about the genetic variants linked to type 2 diabetes could help identify potential therapeutic targets for type 2 diabetes. Researchers also noted that this information could help guide treatment plans for people with the disease who may be susceptible to specific diabetes complications.

Going forward, the researchers plan to conduct a long-term examination of how genetics influence disease progression among patients with type 2 diabetes and associated metabolic disorders. The group is also leveraging the list of newly-discovered genes to investigate medication interactions.

Knowing the genetic susceptibility for diabetes complications in a patient already diagnosed with type-2 diabetes, for example through a cumulative genetic risk score, could help guide that patients care, said co-senior-authorKyong-Mi Chang, MD, a professor of Medicine at Penn, Associate Chief of Staff for Research at VHAs CMCVAMC and the Co-PI for the VHAs MVP Merit Award that supported this work.

As clinicians, we hope that these findings can ultimately be applied to improve the health outcomes for our patients including veterans.

See original here:
Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com